Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557193 | 0.87 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL10726712 | 0.87 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL4919917 | 0.86 | CHRNA7 (0.66) | CHRNA7ALDH1A1PKMHRH3EPHX2 | |
| SCHEMBL4911957 | 0.86 | CHRNA7 (0.66) | CHRNA7ALDH1A1HRH3EPHX2MEN1 | |
| SCHEMBL21940834 | 0.86 | CHRNA7 (0.66) | CHRNA7ALDH1A1HRH3EPHX2MEN1 | |
| SCHEMBL23709723 | 0.85 | ALDH1A1 (0.76) | CHRNA7ALDH1A1HRH3EPHX2MEN1 | |
| SCHEMBL1409824 | 0.85 | CHRNA7 (0.64) | CHRNA7ALDH1A1HRH3EPHX2MEN1 | |
| SCHEMBL6634646 | 0.85 | CHRNA7 (0.64) | CHRNA7ALDH1A1HRH3EPHX2MEN1 | |
| SCHEMBL16809564 | 0.85 | CHRNA7 (0.64) | CHRNA7ALDH1A1HRH3HPGDEPHX2 | |
| SCHEMBL13503740 | 0.85 | CHRNA7 (0.88) | CHRNA7ALDH1A1HRH3HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-8853420-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853420-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| EP-2471787-A1 | New compounds | Boehringer Ingelheim International GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| EP-2404911-A1 | Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives | Janssen Pharmaceutica NV (BE) | 2012-01-11 | — | — | EP | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| WO-2010012747-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263565-A1 | COMPOUNDS | MKI67, CCNA1, CCNT1 | CHRNA7 4271/4885ALDH1A1 65/4885PKM 1271/4885 |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | CHRNA7 4285/4885ALDH1A1 2354/4885PKM 3848/4885 |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | CHRNA7 2390/4885ALDH1A1 295/4885PKM 1829/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | CHRNA7 3560/4885ALDH1A1 293/4885PKM 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.